Summary
Heparan sulfate mimetics, which we have called the PG500 series, have been developed to target the inhibition of both angiogenesis and heparanase activity. This series extends the technology underpinning PI-88, a mixture of highly sulfated oligosaccharides which reached Phase III clinical development for hepatocellular carcinoma. Advances in the chemistry of the PG500 series provide numerous advantages over PI-88. These new compounds are fully sulfated, single entity oligosaccharides attached to a lipophilic moiety, which have been optimized for drug development. The rational design of these compounds has led to vast improvements in potency compared to PI-88, based on in vitro angiogenesis assays and in vivo tumor models. Based on these and other data, PG545 has been selected as the lead clinical candidate for oncology and is currently undergoing formal preclinical development as a novel treatment for advanced cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257. doi:10.1038/35025220
Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410. doi:10.1038/nrc1093
Herbst RS (2006) Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs 11:635–650. doi:10.1517/14728214.11.4.635
Sasisekharan R, Shriver Z, Venkataraman G et al (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2:521–528. doi:10.1038/nrc842
Wegrowski Y, Maquart FX (2004) Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 49:259–268. doi:10.1016/j.critrevonc.2003.10.005
Lever R, Page CP (2002) Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140–148. doi:10.1038/nrd724
Presta M, Leali D, Stabile H et al (2003) Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 9:553–566. doi:10.2174/1381612033391379
Karoli T, Liu L, Fairweather JK et al (2005) Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J Med Chem 48:8229–8236. doi:10.1021/jm050618p
Zetser A, Bashenko Y, Edovitsky E et al (2006) Heparanase induces vascular endothelial growth factor expression: correlation with p38 phosphorylation levels and Src activation. Cancer Res 66:1455–1463. doi:10.1158/0008-5472.CAN-05-1811
Cohen-Kaplan V, Naroditsky I, Zetser A et al (2008) Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123:2566–2573. doi:10.1002/ijc.23898
Vlodavsky I, Elkin M, Abboud-Jarrous G et al (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49:207–210. doi:10.1080/03008200802143281
Cochran S, Li C, Fairweather JK et al (2003) Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem 46:4601–4608. doi:10.1021/jm030180y
Cochran S, Li CP, Ferro V (2008). A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins. Glycoconjuate J. doi:10.1007/s10719-008-9210-0
Bisio A, Mantegazza A, Urso E et al (2007) High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin species to cleavage by heparanase. Semin Thromb Hemost 33:488–495. doi:10.1055/s-2007-982079
McKenzie E, Young K, Hircock M et al (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423–435. doi:10.1042/BJ20030318
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108. doi:10.1016/0006-2952(73)90196-2
Nicosia RF, Ottinetti A (1990) Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26:119–128. doi:10.1007/BF02624102
Min J-K, Han K-Y, Kim E-C et al (2004) Capsaicin Inhibits in Vitro and in Vivo Angiogenesis. Cancer Res 64:644–651. doi:10.1158/0008-5472.CAN-03-3250
Auerbach R, Lewis R, Shinners B et al (2003) Angiogenesis assays: a critical overview. Clin Chem 49:32–40. doi:10.1373/49.1.32
Ferro V, Dredge K, Liu L et al (2007) PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 33:557–568. doi:10.1055/s-2007-982088
Ebos JML, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232–239. doi:10.1016/j.ccr.2009.01.021
Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231. doi:10.1016/j.ccr.2009.01.027
Acknowledgements
The authors acknowledge Dr. Ralf Brandt (vivoPharm, Adelaide, Australia) for the HT29 data, Job Harenberg (University of Mannheim, Germany) for the anticoagulant data and Bruce Wyse (Tetra-Q, Brisbane, Australia) for supply of the rat aortic tissue. We also thank Laurence Marton (Progen Pharmaceuticals Inc., Redwood City, CA) for review of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
Rights and permissions
About this article
Cite this article
Dredge, K., Hammond, E., Davis, K. et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest New Drugs 28, 276–283 (2010). https://doi.org/10.1007/s10637-009-9245-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9245-5